TABLE 1.

Susceptibility results of Mycobacterium peregrinum type II clinical isolates (including two designated reference strains) and two reference strains of M. senegalense

Isolates tested and drug	MIC (μg/ml) for the indicated ATCC reference strain				Type II clinical isolates
	Type II BAA-849	M. peregrinum 35755	M. senegalense		No. tested	MIC (μg/ml)a
			13781	35796T		Range	50%	90%	Mode
Group A (all isolates)
Amikacin	0.5	≤0.25	≤2	≤1	43	≤0.25-4	≤1	≤2	≤1
Cefoxitin	16	8	16	16	43	4-32	16	32	16
Ciprofloxacin	0.25	≤0.063	1	0.5	43	0.25-1	0.5	1	0.5
Doxycycline	1	≤0.25	≤0.12	≤0.12	42	≤0.12-1	≤0.25	0.5	≤0.12
Imipenem	2	≤0.5	4	2	42	0.25-4	1	≤4	1
Sulfamethoxazole	64	≤1	16	16	42	≤1-64	8	32	8
Tobramycin	8	2	4	8	43	1-8	4	8	4
Group B (selected isolates)
Clarithromycin	0.5	≤0.12	0.5	0.25	30	≤0.12-2	0.25	1	≤0.25
Levofloxacin	0.5	≤0.12	0.5	0.5	23	≤0.12-1	0.5	1	0.5
Linezolid	4	≤2	4	≤2	30	1-8	2	8	≤2
Gatifloxacin	0.25	≤0.06	0.25	0.12	24	≤0.12-0.5	≤0.12	0.25	≤0.12
Meropenem	1	2	8	4	24	≤0.5-4	2	4	1, 2, 4

^a50% and 90%, MICs at which 50 and 90% of isolates are inhibited, respectively.